Search

Your search keyword '"Kamada, Koki"' showing total 17 results
Start Over Author "Kamada, Koki"
17 results on '"Kamada, Koki"'

5. Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer.

Author

Sumi, Toshiyuki, Sekikawa, Motoki, Koshino, Yuta, Nagayama, Daiki, Nagahisa, Yuta, Matsuura, Keigo, Shijubou, Naoki, Kamada, Koki, Suzuki, Keito, Ikeda, Takumi, Michimata, Haruhiko, Watanabe, Hiroki, Yamada, Yuichi, Osuda, Koichi, Tanaka, Yusuke, and Chiba, Hirofumi

Subjects
THERAPEUTIC use of antineoplastic agents, RISK factors of pneumonia, PNEUMONIA, RISK assessment, PULMONARY function tests, SQUAMOUS cell carcinoma, DRUG side effects, ANTINEOPLASTIC agents, SEX distribution, SMOKING, PROGRAMMED death-ligand 1, COMPUTED tomography, CANCER patients, RETROSPECTIVE studies, INTERSTITIAL lung diseases, AGE distribution, CHEST X rays, TUMOR markers, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, FIBROSIS, MEDICAL records, ACQUISITION of data, CARBON monoxide, LUNG cancer, NIVOLUMAB, IPILIMUMAB, PULMONARY surfactant
Abstract

Background: The efficacy of anti‐CTLA‐4 antibody (ipilimumab) plus anti‐programmed cell death 1 antibody (nivolumab) in treating advanced non‐small cell lung cancer (NSCLC) is impeded by an elevated risk of severe immune‐related adverse events. However, our understanding of associations among pre‐existing fibrosis, emphysematous changes, and objective indicators as predictive factors is limited for severe pneumonitis in NSCLC patients receiving this combination therapy. Thus, we retrospectively investigated these associations, including overall tumor burden, before treatment initiation in the Japanese population. Methods: We focused on patients (n = 76) with pre‐existing interstitial lung disease (ILD) to identify predictors of severe pneumonitis. Variables included age, sex, smoking status, programmed cell death ligand 1 expression, overall tumor burden, chest computed tomography‐confirmed fibrosis, serum markers, and respiratory function test results. Results: Severe pneumonitis was more frequent in patients with squamous cell carcinoma, fibrosis, low diffusing capacity for carbon monoxide (%DLCO), and high surfactant protein D (SP‐D) level. Notably, squamous cell carcinoma, baseline %DLCO, and SP‐D level were significant risk factors. Our findings revealed the nonsignificance of tumor burden (≥85 mm) in predicting severe pneumonitis, emphasizing the importance of pre‐existing ILD. Conversely, in cases without pre‐existing fibrosis, severe pneumonitis was not associated with %DLCO or SP‐D level (93.2% vs. 91.9%, and 63.3 vs. 40.9 ng/mL, respectively) and was more common in patients with a large overall tumor burden (97.5 vs. 70.0 mm). Conclusion: Vigilant monitoring and early intervention are crucial for patients with squamous cell carcinoma, high SP‐D level, or low %DLCO undergoing ipilimumab plus nivolumab therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Lung adenocarcinoma with tumor resolution and dystrophic calcification after salvage surgery following immune checkpoint inhibitor therapy: A case report

Author

Sumi, Toshiyuki, primary, Uehara, Hirofumi, additional, Masaoka, Toshiaki, additional, Tada, Makoto, additional, Keira, Yoshiko, additional, Kamada, Koki, additional, Shijubou, Naoki, additional, Yamada, Yuichi, additional, Nakata, Hisashi, additional, Mori, Yuji, additional, and Chiba, Hirofumi, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results